Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Prosoria - A New Non-Prescription Treatment System For Psoriasis Symptoms - Now On-Sale Online For First Time
  • USA - English


News provided by

Lawrimore Communications, PR for Prosoria

Feb 13, 2018, 03:00 ET

Share this article

Share toX

Share this article

Share toX

Prosoria is a 3-step treatment process for relieving symptoms of psoriasis
Prosoria is a 3-step treatment process for relieving symptoms of psoriasis
Youtube
Youtube

FT. WORTH, Texas (PRWEB) February 13, 2018 -- Prosoria™, a new non-prescription treatment for relieving and helping prevent the symptoms of psoriasis, is now available for sale to the public for the first time. Prosoria™ is available to purchase online at https://prosoria.com as well as on amazon.com.

"There is a huge need for Prosoria," explained Art Clapp, CEO of Nuvothera Inc. which manufactures Prosoria™. "Psoriasis is the world's largest autoimmune disease, affecting more than eight million people in the U.S. and 125 million worldwide."

Post this

"There is a huge need for Prosoria," explained Art Clapp, CEO of Nuvothera Inc. which manufactures Prosoria™. "Psoriasis is the world's largest autoimmune disease, affecting more than eight million people in the U.S. and 125 million worldwide. Yet research shows that 87.8 percent of patients and 98.0 percent of dermatologists feel there is a strong or moderate need for better psoriasis therapies.

"Prosoria is the first once daily, three-step psoriasis treatment system proven to effectively relieve the symptoms of psoriasis and help prevent recurrences," Clapp said. "Its safety and effectiveness was recently recognized by the National Psoriasis Foundation's prestigious Seal of Recognition."

"In addition to the medical challenges, psoriasis can also have a significant psychosocial impact on the lives of people living with the condition," said Clapp. "We have heard personal stories from people who were afraid to wear shorts or expose their skin or experienced rejection from employers for jobs and in relationships. Their self-esteem and confidence are often affected."

Karl Woolfenden of Dallas, TX, an early test user, said that compared to other treatments, Prosoria™ "was amazing. With this product, I tried it, I saw results. I didn't have any side effects. It was easy to use, easy to apply. I would say I had about 25 percent coverage, mainly on my legs, my knees and my elbows. Since using the product that has completely reduced down. I would say now I'm about 2 percent covered. So with a little bit more time, I feel I'll be 100 percent free."

Vickie Wilkerson of Shreveport, LA, said Prosoria™ began working for her right away. "It was immediate. Within a couple of days, I could tell a difference. You get these big red raised areas and to see them being like normal skin, like at a normal level - that was amazing…. I was floored because it was the first thing that actually worked for me in 14 years."

See and hear how other users have benefited from Prosoria™, on the company website https://www.prosoria.com/pages/results.

"Prosoria combines both clinical strength and natural pro-botanical ingredients that help relieve psoriasis symptoms while softening and restoring the appearance of skin," said Bev Hope, Nuvothera Marketing Director. "The products were formulated to feel light and silky on the skin. They are steroid free, fragrance free, and paraben free, and they are safe and gentle to use every day.

The treatment system consists of four products. It includes three pump bottles of gels and a cream for the daily system plus a tube of Prosoria™ Rapid Repair Exfoliating Ointment for more intensive night care, Hope said. The Prosoria™ Daily Psoriasis Treatment System was designed to:
• Hydrate and condition affected skin
• Treat and relieve scaling, flaking, itching, redness, irritation
• Moisturize and exfoliate the skin, leaving it feeling softer and smoother
• Restore the appearance of skin and improve skin texture

To learn more about the new Prosoria™ Daily Psoriasis Treatment System, visit https://prosoria.com/.

About Nuvothera

Founded in 2014 and based in Ft. Worth, TX, Nuvothera was formed with the mission to develop novel OTC products for difficult-to-treat skin diseases such as psoriasis, incorporating natural botanical ingredients and using the latest in scientific knowledge and evidence-based research. The company's primary focus is psoriasis. The management team consists of seasoned dermatology pharmaceutical executives committed to meeting the needs of the individual having psoriasis and partnering with the psoriasis community. Both dermatologists (MDs) and scientists (PhDs) were involved in developing Prosoria™. Prosoria™ products are dermatology and clinically tested.

Buck Lawrimore, Lawrimore Communications, PR for Prosoria, +1 7043324344, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.